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E-mail address: r.sandhoff@dkfz.deForecort membranes of all mammalian cells contain, in addition to phosphoglycerolipids and cho-
lesterol, substantial amounts of sphingolipids. In most cells the acyl moieties of these sphingolipids
are of long chain type (C16–24) and often saturated. However, epidermal keratinocytes and male
germ cells largely express sphingolipids with very long chain-acyl moieties (C26–C36) during their
differentiation and maturation. This expression seems to depend on CerS3, one of six ceramide syn-
thases. However, the complex biosynthetic sequence for both epidermal and testicular sphingolipids
has not been elucidated completely. Whereas it is established that omega-hydroxylated very long
chain-sphingolipids are essential for proper skin barrier function, the role of polyunsaturated very
long chain-sphingolipids (ceramides, sphingomyelins and glycosphingolipids) in differentiating
spermatocytes/spermatids is just beginning to be revealed.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Expression and function
The major fatty acid species incorporated into membrane lipids
of mammalian cells are between 16 and 24 carbon atoms in length.
In phosphoglycerolipids they are saturated, mono- or polyunsatu-
rated. Arachidonic acid (C20:4,x-6/D5) is an example of a common
polyunsaturated fatty acid found in phosphoglycerolipids. Mem-
brane sphingolipids, however, are mainly built up with saturated
fatty acids. One of the most common unsaturated fatty acids in
sphingolipids is nervonic acid, an x-9/D15 monounsaturated com-
pound, which is a major component of cerebrosides and sulfatides
from myelin sheaths. In spermatozoa/testes and in the epidermis
sphingolipids were found whose ceramide moieties consist of a
sphingoid base which is linked to very long chain acyl moieties
consisting of 28–36 carbon atoms, either polyunsaturated or x-
hydroxylated.
1.1. Spermatozoa/testes and fertility
The testis is composed of two functional compartments: (i) the
seminiferous tubules, containing developing germ cells and sup-
porting Sertoli cells, and (ii) the steroidogenic Leydig cells in the
interstitium [1,2]. Mammalian spermatogenesis, i.e. the transfor-
mation of diploid spermatogonia into haploid spermatozoa, is a
complex process. It commences with the asymmetric division of
spermatogonia, which are located in the basal compartment ofchemical Societies. Published by Ethe seminiferous tubules. This followed by proliferation and differ-
entiation into preleptotene and leptotene spermatocytes. The lat-
ter have to migrate into the adluminal compartment of the
seminiferous tubules and must cross the blood testis barrier
(BTB). Tight junctions contribute to the establishment of the BTB,
which is made up of adjacent Sertoli cells and which physically
segregates post-meiotic germ cells from nutrients and biomole-
cules in the systemic circulation [2,3]. In order to maintain the
adluminal milieu the BTB is working like a sluice [4]. After comple-
tion of meiosis germ cells turn into haploid round spermatids. The
ongoing and brisk transcription in round spermatids causes upreg-
ulation of speciﬁc proteins. In spermatogenesis, only the ﬁrst cell
division is complete and leads to two separate daughter cells. All
consecutive cell divisions result in a growing ‘‘string of beads” of
interconnected sister germ cells, due to incomplete cytokinesis.
The intercellular bridges may be observed by immunoﬂuorescence
or electron microscopy. In the ultimate phase of spermatogenesis
male germ cells undergo cytological transformations, which in-
clude a change of shape, nuclear condensation, and development
of specialized structures, such as an acrosome, and a ﬂagellum
with a mitochondrial sheath. Finally, mature spermatozoa are re-
leased from their residual bodies into the lumen of the seminifer-
ous tubules (spermiation) to be transported to the epididymis
(Fig. 1B) [2].
The ﬁrst report on polyunsaturated fatty acid moieties as part of
sphingolipids dates from 1987 when Poulos and co-workers ana-
lysed sphingomyelins of ram spermatozoa for their acyl composi-
tion. Besides sphingomyelin species with saturated and x-9
mono-unsaturated long chain acyl residues they found specieslsevier B.V. All rights reserved.
Fig. 1. Schematic drawings of spermatogenesis in mice (B) including testicular sphingolipid structures: (A) the ceramide moiety, and (C) complex gangliosides. Modieﬁed
from [7]. (A) Ceramide moieties of testicular sphingolipids consist of a d18:1-sphingosine base to which a fatty acid is linked through an amide bond. In case of interstitial
cells, Sertoli cells and germ cells of the basal compartment, these fatty acid moieties are of long-chain and saturated (mainly palmitic acid), whereas in the case of adluminal
germ cells and spermatozoa, they are of very long-chain (C28–32) and polyunsaturated (5–6 double bonds). The sphingolipid head group (R) may be ceramide (H),
phosphorylcholine (sphingomyelin), Glc, Lac,Gb3–5, or a complex ganglioside oligosaccharide in case of somatic cells (e.g. Sertoli, Leydig cells, myoﬁbroblasts) and ceramide,
phosphorylcholine, Glc, Lac, and acidic or neutral fucosylated complex ganglio series oligosaccharides (see C) in case of germ cells. (B) Supporting Sertoli cells (red) adhere to
the basal lamina (BL) and develop in addition to the BTB several junctions and specialized contacts to germ cells during all differentiation stages. Spermatogonia (SG) are also
adherent to the basal lamina. Spermatogonia type A divide and develop into spermatogonia type B, which enter meiotic prophase and differentiate into primary
spermatocytes (SC, preleptotene (plSC)? leptotene (lSC)? zygotene? pachytene (pSC)). Pachytene spermatocytes have traversed the BTB and complete meiosis within the
adluminal compartment. Four round haploid spermatids arise from one pachytene spermatocyte and undergo spermiogenesis in 16 steps, including elongated spermatids
(eST). Axial components of spermatids are gradually extruded, while cellular structures (syncytial mass – residual bodies, rb), which are not components of mature
spermatozoa (Sza) remain in the epithelium. Finally, spermatozoa are released into the tubular lumen and the segregated residual bodies are phagocytized (prb) by Sertoli
cells. Testosterone producing Leydig cells (LC) are located in the interstitium (IS) between adjacent tubules. (C) Spermatogonia and basal germ cells express sialo-compound A
(s.Cp.A, FucGM1, IV2-a-Fuc,II3-a-NeuNAc-Gg4Cer) with LC-FAs, pachytene spermatocytes, round and elongating spermatids synthesize four complex asialo-glyco-
sphingolipids compounds A–D, with VLC-PUFAs. Compounds B–D are derivatives of Cp.A (Cp.A, FucGA1, IV2-a-Fuc-Gg4Cer; Cp.B: IV3-a-Gal-FucGA1; Cp.C: IV3-a-GalNAc-
FucGA1; and IV3-a-GalNAcb3Gal-FucGA1). Elongating spermatids additionaly sialylate these compounds giving rise to four complex gangliosides with VLC-PUFAs: sialo-
Cp.A-D (s.Cp.A-D; s.Cp.A: II3-a-NeuNAc-Cp.A, FucGM1; s.Cp. B: IV3-a-Gal-FucGM1; Cp.C: IV3-a-GalNAc-FucGM1; and IV3-a-GalNAcb3Gal-FucGM1).
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4–6 double bonds. Interestingly, these polyenoic acyl moieties
where very long. They had a length between 28 and 34 carbon
atoms and are abbreviated in this review as VLC-PUFAs.1 VLC-PU-
FAs were exclusively bound to sphingomyelin but not to other phos-
phoglycerolipids and were estimated to make up 9% of the total
phospholipid content. However, Poulos and colleagues did not detect
sphingomyelins with polyunsaturated acyl chains shorter than 28
carbon atoms [5] although long chain-PUFAs (LC-PUFAs) like docosa-
hexaenoic acid (C22:6, x-3/D4), docosapentaenoic acid (C22:5, x-6/
D4), or arachidonic acid (C20:4, x-6/D5) moieties are major PUFAs
found in other phosphoglycerolipids and cholesterylesters of sper-
matozoa or testis [6–8]. VLC-PUFAs appeared to be typical for mam-
malian spermatozoa/testes and may be a-hydroxylated depending
on the mammalian species [8–10]. These VLC-PUFAs were part of
testicular and spermatozoon sphingomyelins [11]. VLC-PUFAs with
more than 28 carbon atoms are also detected in retina and brain.
However, in retina and brain these VLC-PUFAs are part of phospho-
glycerolipids like phosphatidylcholine [12–16], for a detailed review
see [8].
Our investigatons on fertile and infertile mouse models of inter-
rupted glycosphingolipid (GSL) biosynthesis revealed in addition to
sphingomyelin a class of fucosylated complex GSLs of the ganglio-
series in mouse testes that contained almost exclusively VLC-PU-
FAs with a length of 26–32 carbon atoms and 4–6 double bonds
(Fig. 1C). Whereas the synthesis of the acidic subset (fucosylated
gangliosides) was blocked in fertile (GM3 synthase deﬁciency,
Siat9d/d) and infertile (GalNAc transferase deﬁciency, B4galnt1d/d)
mice, the neutral subset of fucosylated GSL was missing only in1 VLC-PUFA: very long chain-polyunsaturated fatty acid. In this review ‘‘very long”
deﬁnes fatty acids with 28 or more carbon atoms in length. ‘‘Long” fatty acids will
summarize all fatty acids with a length of 16–26 carbon atoms.the infertile mouse model [17]. One of these neutral glyco-struc-
tures, Cp.D (IV3-a-GalNAcb3Gal,IV2-a-Fuc-GA1), had already been
described in rat testes [18] and the analysis of its ceramide anchor
with electrospray mass spectrometry revealed almost exclusively a
VLC-PUFA content [17]. Infertile GalNAc transferase deﬁcient mice
have been established independently from two groups [19,20] and
both strains have an arrest in spermatogenesis at the end of meio-
sis when round spermatids are formed. As mentioned above, round
sister spermatids, derived from a single spermatogonial stem cell
are interconnected by intercellular bridges as a result of incom-
plete cytokinesis in spermatogenesis. Hence, these sister sperma-
tids share a single plasma membrane. Lacking complex GSL,
these intercellular bridges disappear and plasma membranes of
the spermatid clones round up resulting in multinuclear giant cells.
They undergo apoptosis and are taken up by Sertoli cells with the
consequence of male infertility [17,21]. Additionally, serum levels
of testosterone were 20-fold reduced in these mice and it was as-
sumed that gangliosides play a role in secretion of testosterone
synthesized by Leydig cells [21]. However, complex GSLs with
VLC-PUFAs may be essential for the stability of intercellular
bridges between spermatids, the polarization of elongating sper-
matids and/or the stability of the spermatid – Sertoli cell contact.
Interestingly, VLC-FAs or their biological derivatives have also been
linked to function in proper furrow ingression during cytokinesis in
Drosophila spermatocytes [22]. However, as the simple GSL VLC-
PUFA-lactosylceramide remains in GalNAc transferase deﬁcient
mouse testes, it may be speculated that a more complex carbohy-
drate moiety of the glycolipid-structure is essential, e.g. for binding
to a lectin. Yet, fucosylation of these compounds is not essential, as
mice with a deﬁciency in fucosylation express the corresponding
non-fucosylated GSL structures and have normal spermatogenesis
and are fertile [7]. Combining the biochemical and immunohisto-
logical data we concluded that during spermatogenesis complex
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cells/spermatogonia fucosylated ganglioside FucGM1 (sialo-Cp.A)
is build up with LC-FA anchors. It disappears in adluminal spermat-
ocytes and round spermatids which now express a series of four
neutral complex glycolipids (Cp.A-D) including FucGA1 (Cp.A),
now with VLC-PUFA anchors. Finally, elongation of spermatids
coincides with de novo synthesis of gangliosides (sialo-Cp.A-D),
but now with VLC-PUFA moieties (Fig. 1A and C) [7,17]. Investigat-
ing mouse testes during the initial wave of spermatogenesis it was
concluded that not only fucosylated GSL, but also ceramides and
sphingomyelins with VLC-PUFA content ﬁrst appear together with
pachytene spermatocyte stages. Thus these sphingolipids are con-
nected to differentiating germ cells of the adluminal compartment
[7]. They all have traversed the blood testis barrier, which itself is
acting as a sluice [4] in order to maintain the specialized luminal
milieu of the seminiferous tubules. Perhaps this milieu could trig-
ger VLC-PUFA sphingolipid synthesis. In rat testes, VLC-PUFA cera-
mides and sphingomyelins were also reported to ﬁrst appear in
spermatocytes 25–27 after birth [23] and these compounds are
the major group of sphingomyelins and ceramides in the head of
mammalian spermatozoa [24]. By this, VLC-PUFA ceramides and
sphingomyelins may also be important during sperm capacitation,
i.e. a biochemical event taking place in the female reproductive
tract. It is the next to last step in the maturation of mammalian
spermatozoa required to render them competent for oocyte fertil-
ization. Furland and colleagues observed that spermatozoon sphin-
gomyelins were degraded to ceramides upon treatment of
spermatozoa with sperm capacitating agents such as calcium,
bicarbonate, and albumin, thus decreasing several fold the SM/
Cer ratio in rat spermatozoa [23]. Loss of the phophatidylcoline
head group from sphingomyelin in sufﬁcient amounts changes
the biophysical properties of corresponding membranes [25–27].
Therefore, the hydrolysis of sperm head VLC-PUFA sphingomyelins
may be an early step among the biochemical and biophysical
changes in the spermatozoon preceding fertilization [23]. The
molecular mechanism by which sphingolipids with VLC-PUFA moi-
eties could function during spermatogenesis and capacitation is
still unclear and demands further investigation of novel mouse
models and subcellular localisations of VLC-PUFA sphingolipids
and their interacting molecular environment.
1.2. Epidermis and water permeability barrier (WBP)
Another rich source of sphingolipids with very long chain fatty
acid moieties (VLC-FAs) with up to 36 carbon atoms in length is the
epidermis of mammalian skin. The majority of these epidermal
VLC-FAs with more than 26 Carbon atoms in length is x-hydroxyl-
ated and may be unsaturated (1 or 2 double bonds) but not poly-
unsaturated. Sphingolipids made up with these VLC-FAs are
ceramides and glucosylceramides [28,29].
The primary function of the epidermis is to build up a protective
WPB, a pre-requisite for land dwelling animals in order to avoid
desiccation. Additionally, it is an important physical barrier against
pathogen invasion and contains antimicrobial peptides [30]. The
WPB forms late in embryogenesis and is thought to be established
by tight junctions within the stratum granulosum, as well as by
layers of corniﬁed cells (corneocytes) embedded in a matrix of
extracellular lipid lamellae within the stratum corneum. The anu-
clear corneocytes are interconnected by desmosomal proteins and
ﬁlled with keratin ﬁlaments bound to a peripheral corniﬁed enve-
lope composed of a series of cross-linked proteins. Serveral layers
of corneocytes provide a resilient framework for the intercellular
lipid stacked sheets [31–34]. These sheets consist largely of choles-
terol, free fatty acids and ceramides [35–37]. Ceramides with VLC-
FAs are part of these stratum corneum intercellular lipid lamellae
but rather not of the cellular plasma membranes. The lipids of thisextracellular matrix are synthesized intracellularly by keratino-
cytes in the strata spinosum and granulosum and form disk-like, li-
pid membrane structures within specialized vesicles, the lamellar
bodies. The latter transport their content to the cell surface where
it is ﬁnally secreted shortly before the cells transform into corneo-
cytes (Fig. 2) [38–41]. The ATP binding cassette transporter
ABCA12 appears to be an important player for the correct loading
of these lamellar bodies. Mutations or lack of this compound in hu-
mans and in related mouse models results in Harlequin ichthyosis
causing impaired skin barrier function and neonatal death. It is
associated with lamellar bodies lacking lamellar sheets [42–44].
VLC-FA ceramides are found mainly esteriﬁed via their x-hydroxy
group. Thereby, they are either bound to long chain fatty acids,
especially linoleic acid, or to glutamate residues of corniﬁed enve-
lope proteins [28,29,45–47]. Especially linoleoyl x-esteriﬁed cera-
mides were shown to be about tenfold reduced in ABCA12
deﬁciency [42].
Besidesx-hydroxy ceramides, in lower concentrations the total
epidermis also contains corresponding x-hydroxy GlcCer, which
are esteriﬁed in x-position to linoleic acid [29,48,49]. In ABCA12
deﬁciency linoleic acid esteriﬁed x-hydroxy GlcCer increased ﬁve
fold but not nearly to the extent by which corresponding esteriﬁed
ceramides disappear [42], suggesting that the glucosyl derivatives
are loaded through an ABCA12 dependent mechanism into lamel-
lar bodies. In Gaucher disease andrelated mouse models, the
amount of x-hydroxy ceramides also decreases dramatically but
corresponding x-hydroxy GlcCer increase to about the same ex-
tent [50–52]. In mouse models of decreased lysosomal glucocere-
brosidase activity or prosaposin (encoding the activator proteins
Sap-A, -B, -C, and –D) deﬁciency also protein-bound GlcCer was de-
tected for the ﬁrst time, as it strongly accumulated in the epider-
mis [50,52]. Later it could be shown, that the covalent
attachment of ceramides or glucosylceramides correlates with
the maturationof the stratum corneum and establishment of the
WPB shortly before birth [53]. Lysosomal enzymes and proteins
like the acidic sphingomyelinase (SMPD1), acidic glucosylcerami-
dase (Gba1), and sphingolipid activator proteins are also secreted
in the upper granular layer [41,54]. Taken together, it was con-
cluded that x-linoleoyl-glucosylceramides are the intracellular
transport form of these lipids and are substrates for transesteriﬁca-
tion onto proteins [55]. In a process of extracellular lipid modiﬁca-
tion free and protein boundx-hydroxy glucosylceramides then are
degraded to x-hydroxy ceramides and in part to xh-VLC-FAs
(Fig. 2) [55–57].
The protein bound sphingolipids and VLC-FAs link the corniﬁed
envelopewith the intercellular lipid lamellae. This linkagemayserve
as a chaperonal frame work for correct lamellae formation [55].
In ‘‘collodion babies” affected by Gaucher disease type II in its
most severe form, as well as in corresponding mouse models, the
epidermal accumulation of x-hydroxy GlcCer at the expense of
corresponding ceramide structures leads to a neonatal ichthyosis
phenotype with scaling abnormalities and a severely impaired
WPB [50–52,58].
A prerequisite for the extracellular degradation of GlcCer to
ceramides is preceding intracellular synthesis of GlcCer from cera-
mides by the glucosylceramide synthase. Deletion of this enzyme
in basal mouse keratinocytes led to epidermal GlcCer deﬁciency
and increased non-esteriﬁed x-hydroxy ceramides in 4 day old
mice [59]. The increased free x-hydroxy ceramides could indicate
that glucosylation precedes x-esteriﬁcation (Fig. 2). However, in
these mice the onset of glucosylceramide synthase deﬁciency as
a consequence of keratinocyte-restricted Cre-recombinase action
is not complete until birth. The lifespan of these mice (4–5 days)
then is too short for a complete epidermal turnover. Therefore,
esteriﬁed and protein bound ceramides were still detected. Never-
theless, these sphingolipid changes were accompanied by a severe
Fig. 2. Establishment of extracellular lipid lamellae essential for the epidermal water permeability barrier with the focus on very long chain x-hydroxy sphingolipids. Left:
The schematic drawing illustrates the strata of the epidermis. KG, keratohyalin granula. Enlargement on top is showing lamellar bodies (LB) in granulocytes and there
exocytosis at the interface to the stratum corneum. Red lines between the cells represent intercellular lipid lamellae. Right: Further enlargement of the interface illustrating
intracellular sphingolipid synthesis and transport as well as their extracellular processing. At the endoplasmic reticulum (ER) VLC-FA-CoAs are synthesized involving Elovl4.
They are condensed with sphingosine by CerS3 to yield very long chain ceramides (introduction of the x-hydroxy group is not taken into account as it is not clear yet, at
which level it is established). At the site of the Golgi apparatus glucosylceramide synthase (GlcCerS) converts ceramides into GlcCer, and GlcCer may ﬂip with its head group
into the Golgi lumen. LBs likely form at the trans-Golgi-network (TGN). The molecular details are not clear. ABCA12, located on LBs is a prerequisite for intravesicular lipid
lamellae formation. CGI-58, associated to LBs is involved in the transfer of linoleic acid from triglycerides to the x-hydroxy group of sphingolipids (very likely GlcCer).
However, Akiyama et al. state that CGI-58 is localized within LBs [98]. Fusion of LBs with the plasma membrane releases disc-like lipid structures, into the intercellular space.
Extracellularily, transesteriﬁcation (T.E.) leads to protein bound GlcCer. Secreted enzymes and co-factors process GlcCer to Cer, and in some part to fatty acids (and
sphingosine), either protein bound or ‘‘free” within the lipid lamellae (which contain also cholesterol, not shown). Lower part: Chemical structure of typical epidermal GlcCer
esteriﬁed with their x-hydroxy group to linoleic acid.
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at most. No lamellar discs, but disordered structures were found in
the lamellar bodies of these mice, demonstrating that intracellular
GlcCer synthesis and its subsequent extracellular hydrolysis are in-
volved in extracellular ceramide formation and are essential for
correct assembly of intercellular lamellar sheets [59]. The order
and molecular mechanisms by which long chain fatty acids and
speciﬁcally linoleic acid are hooked onto the xh-VLC-FAs of
epidermal (glucosyl)ceramides has not been clariﬁed. However, a
recent study on CGI-582 adds an important piece to the puzzle.2 CGI-58: Comparative gene identiﬁcation-58, also designated as a/b-hydrolase
domain containing-5 (ABHD-5).CGI-58 has been reported to be a lipid droplet-associated acyl trans-
ferase that acylates lysophosphatidic acid and activates adipose tri-
glyceride lipase (ATGL) [60–64]. Whereas ATGL deﬁciency was not
reported to be associated with epidermal skin alterations [65],
CGI-58 deﬁcient mice surprisingly revealed a severe skin permeabil-
ity barrier defect leading to neonatal lethality. CGI-58 deﬁcient mice
are completely devoid of x-acyl esteriﬁed ceramides. Free xh-cera-
mides accumulate and protein bound ceramides decrease sixfold.
The knockout is associated with an ATGL independent defect in
the hydrolysis of epidermal triglycerides; and labelling experiments
indicate that sequestration of fatty acids in triglycerides prevents the
synthesis of x-acyl ceramides [66]. Thus, CGI-58 is an intracellular
key player of intercellular lipid lamellae formation (Fig. 2). The
R. Sandhoff / FEBS Letters 584 (2010) 1907–1913 1911strong decrease in protein bound ceramides may also indicate that
linoleoyl x-esteriﬁed compounds are precursors for protein attach-
ment. However, the residual amount of protein bound ceramides
seems to be derived from another, linoleoyl x-esteriﬁcation inde-
pendent pathway.
2. Synthesis of VLC-(PU)FA sphingolipids
The synthesis of sphingolipids with VLC-(PU)FA moieties needs,
in addition to the biosynthetic machinery of ‘‘conventional” sphin-
golipid synthesis [31], two requirements. The ﬁrst is a special
machinery for the elongation of fatty acids in order to produce
the corresponding substrate acyl-CoAs. Secondly, a ceramide syn-
thase, that has a decent afﬁnity for these VLC-acyl-CoA substrates
is needed.Fig. 3. Biochemical reactions of very long chain-fatty acid synthesis (A) and production
with malonyl-CoA, subsequently reduced to a 3-hydroxy compound, dehydrated to a a,b
the ER membrane.B) Ceramide synthases located within the ER membrane condensate an
from the salvage pathway (sphingosine from lysosomal degradation). Each of the six CerSFirst, the elongation of fatty acids beyond the length of 16 car-
bon atoms is performed by a membrane bound FA-elongation sys-
tem. The four step biochemical cycle of these ER resident
complexes starts with the condensation of an acyl-CoA precursor
with malonyl-CoA, followed by the reduction of the resulting 3-
keto acyl-CoA intermediate to D(R)-3-hydroxy acyl-CoA, which is
subsequently dehydrated. Finally the 2-enoyl species is reduced
to yield an acyl-CoA that is, after one round of the elongation cycle,
elongated by two methylene groups (Fig. 3A) [67]. Elovl (elonga-
tion-of-very-long-chain-fatty acids) genes encode for a large fam-
ily of proteins required for the condensation step in the
elongation cycle and determine the rate of overall fatty acid elon-
gation. Furthermore, with their substrate speciﬁcity and distinct
tissue expression pattern, they determine the type and length of
VLC-FAs expressed in different cell types. Seven fatty acid elongaseof (dihydro)ceramide (B). (A) Long chain-acyl CoAs are elongated by Elovl-proteins
-trans enoyl-CoA, and further reduced to a saturated and elongated acyl-CoA within
acyl-CoA with a sphingoid base, either from de novo biosynthesis (sphinganine) or
found in mammals has different afﬁnities towards the length of acyl-CoA substrates.
1912 R. Sandhoff / FEBS Letters 584 (2010) 1907–1913subtypes (Elovl1-7) have been identiﬁed in the mouse, rat, and hu-
man genomes [68–73]. By reconstituting the fatty acid elongation
cycle in artiﬁcial proteoliposomes, Denic and Weissman could
demonstrate that proteins of the ELOVL family are the condensing
enzymes specifying the VLC-FA length by a molecular calliper
mechanism [74].
Quantitative RT-PCR revealed strong expression of Elovl1, -2,
and -5 in mouse testis, but also Elovl3, -4 and -6 were detectable.
Until yet, Elovl1, -3 and -4 were found in skin [69]. The epidermal
barrier of Elovl3-deﬁcient mice display a sparse hair coat, a hyper-
plastic pilosebaceous system, and a disturbed hair lipid content. As
Elovl3 expression in skin is restricted to sebaceous glands and the
epithelial cells of the hair follicles, these mice show, however, no
alterations of ceramide levels including those containing VLC-
FAs. Furthermore, homozygote mice are fertile [75]. However,
deletion or mutation of Elovl4 in mice leads to neonatal death
due to a severely impaired WPB. In these mice epidermal VLC-
FAs with more than 28 carbon atoms were absent together with
corresponding x-hydroxy ceramides [76–79]. Interestingly, in
these mice speciﬁcally those fatty acids with a chain length of 26
carbon atoms and corresponding ceramides increased, indicating
acyl-CoAs with a length of 26 carbon atoms (but not shorter) to
be substrate for Elovl4 [76,79]. Thus, Elovl4 rather than Elovl3 is in-
volved in the synthesis of very long chain x-hydroxy fatty acids
that serve as substrates for the synthesis of linoleic acid esteriﬁed
and protein bound ceramides. Whether it is also involved in the
production of testicular VLC-PUFAs still awaits further investiga-
tion. Nevertheless, VLC-PUFA synthesis may be co-regulated with
VLC-PUFA sphingolipid synthesis, as VLC-PUFAs appear during
the puberal testicular maturation together with their correspond-
ing sphingolipids [7].
Secondly, acylation of the sphingoid bases is catalyzed by a
sphinganine-N-acyltransferase that in addition N-acylates sphin-
gosine from the ‘‘salvage pathway”, directly yielding ceramide.
Therefore, this enzyme is now termed simply as a ceramide syn-
thase (CerS, Fig. 3B) [80–84]. Whereas in drosophila only a single
gene encoding a ceramide synthase has been detected [85], recent
observations in several laboratories have established a family of
ceramide synthases in mammals (six in both mice and men), all
of which contain a Lag1p motif that is involved in (dihydro)cera-
mide synthase activity. These CerS proteins are encoded by genes,
which until now are called longevity assurance (Lass) genes. In
addition, CerS2–6 contain a Hox domain [82,86]. These Hox do-
mains containing CerS proteins do not seem to need further sub-
units/co-factors for (dihydro)ceramide synthase activity, as has
been demonstrated for the Hox domain containing CerS5 (Lass5)
[87]. Individual members of the CerS family show different sub-
strate-speciﬁcity towards the chain-length and saturation grade
of the acyl-CoA substrates. The length of the investigated acyl-CoAs
ranged between 14 and 26 carbon atoms within the acyl moiety.
Hence, predictions for the synthesis of VLC-(PU)FA sphingolipids
in skin and testes are restricted. Nevertheless, acyl-CoAs with 24
and 26 carbon atoms appeared to be best incorporated by CerS2
and CerS3. Whereas CerS2 is widely distributed, CerS3 appears to
be restricted to testes and skin [86–93]. Recently, CerS2 deﬁcient
mice have been established that did not suffer from an obvious
skin phenotype [94]. Therefore, it is likely that CerS2 is not essen-
tial for the epidermal biosynthesis of very long chain omega-hy-
droxy sphingolipids. CerS3, however, correlates in its tissue
expression during germ cell and keratinocyte differentiation with
the appearance of VLC-(PU)FA sphingolipids, thereby strongly sug-
gesting its involvement in the synthesis of sphingolipids with very
long chain acyl moieties [7,95]. Enzyme assays with recombinantly
expressed CerS2 and CerS3 in mammalian cells using acyl-CoAs
longer than 26 carbon atoms in length suggest that CerS3 could
be the only mammalian ceramide synthase with an afﬁnity forsuch very long substrates (Rabionet and Sandhoff, unpublished
data). If so, CerS3 may very well be connected to a subset of phe-
notypes with so far unknown origin of human skin diseases and/
or male infertility.
Future investigations should clarify which of the six ceramide
synthease are involved in the biosynthesis of the various epidermal
and testicular sphingolipids with VLC-(PU)FAs. Is a single ceramide
synthase responsible or is their a certain redundancy? How is the
synthesis of ceramides with VLC-(PU)FAs regulated during cell
maturation and do sphingolipids with VLC-FAs themselves regu-
late cellular maturation? Apparently biosynthesis of VLC-(PU)FAs
and corresponding ceramides are co-regulated as observed in testis
[7]; Most recently, it was demonstrated that epidermis speciﬁc
sphingolipid production as well as regulation of fatty acid elongas-
es and WPB formation in part involves vitamin D receptor and its
coactivators [96]. In addition, ceramides themselves including
the artiﬁcal short chain C2- and C6-ceramides stimulates ABCA12
expression via PPARD in human keratinocytes [97]. Whether this
holds also true for epidermis-speciﬁc ceramides with VLC-FAs is
unclear. If so, the molecular mechanism would differ from recent
models as ceramides with VLC-FAs are more or less unsoluble. In
the context of regulation and cell differentiation, ceramide syn-
thase proteins themselves could be important players, and the
function of their Hox domains (CerS2–6) may be a key aspect. To
understand the functions of CerS, information on their detailed
structures will be needed as well as knowledge on the protein net-
work, they are integrated into. Likewise, elucidating the lipid and
protein network into which sperm cell sphingolipids with polyun-
saturated fatty acids are embedded, will be a prerequisite to under-
stand their functions in more detail.
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